Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ampio Pharmaceuticals (NY: AMPE )

1.790 USD -0.050 (-2.72%)
Streaming Delayed Price Updated: 3:52 PM EDT, Jun 23, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,304,886
Open 1.850
Bid (Size) 1.790 (90)
Ask (Size) 1.800 (44)
Prev. Close 1.840
Today's Range 1.790 - 1.890
52wk Range 0.5300 - 2.980
Shares Outstanding 195,689,128
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® Index
From PR Newswire
Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAK
New integrated analysis reinforces Ampion's position as the first novel therapy to demonstrate clinical efficacy over saline for patients suffering from severe OAK 
From PR Newswire

Performance

YTD
+20.95%
+20.95%
1 Month
-6.28%
-6.28%
3 Month
+4.68%
+4.68%
6 Month
-35.14%
-35.14%
1 Year
+198.58%
+198.58%

More News

Read More
Hot Penny Stocks to Buy? 3 to Watch As Vaccine Rates Hit New Highs
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India
From PR Newswire
Ampio Pharmaceuticals to Present at the 2021 International Society for Pharmaceutical Engineers Annual Meeting and Expo
From PR Newswire
Ampio Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Summer Healthcare Symposium
From PR Newswire
Ampio Pharmaceuticals to Present Poster at the International Society for Aerosols in Medicine (ISAM) 23rd International Congress
From PR Newswire
Ampio Pharmaceuticals Receives Investigational Review Board Approval for its Phase I Long COVID-19 Trial (AP-018)
From PR Newswire
Ampio Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
From PR Newswire
Ampion™ Reduces All-cause Mortality in COVID-19 Respiratory Distress by Nearly 80%
From PR Newswire
Ampio Pharmaceuticals Provides Updates on Clinical Programs for Ampion™ in Osteoarthritis and COVID-19
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.